Lenalidomide Maintenance Improves Survival in Poor Prognosis DLBCL
Lenalidomide maintenance significantly improves survival in patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT).
Source: CancerNetwork - Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Conferences/ASH 2016 Leukemia & Lymphoma News Source Type: news
More News: Cancer & Oncology | Conferences | Leukemia | Lymphoma | Revlimid | Stem Cell Therapy | Stem Cells | Transplants